Hyflux ties up with CGH for clinical trials on ELO products' effect on diabetics

HYFLUX signed an agreement with Changi General Hospital (CGH) to conduct two clinical trials to establish the effectiveness of Hyflux's ELO Water and ELO Gel on diabetes control and diabetic foot ulcer patients.

It also announced a committment of up to S$2.5 million in cash and in kind to human clinical trials to further ascertain the scientific merits of ELO Water.

The trials with CGH will study whether patients with diabetes can obtain better glycaemic control by drinking ELO Water in addition to their ongoing lifestyle and medical treatments, and whether diabetic foot or ankle ulcers can be treated with ELO Water bath and ELO Gel.

The principal investigator of both trials is Joan Khoo, senior consultant and chief of endocrinology at CGH.

"The partnership between Hyflux and CGH represents our commitment to further ascertain the scientific merits and efficacy of ELO Water and ELO Gel on diabetes care," said Olivia Lum, executive chairman and group CEO of Hyflux. "If the trials are successful, it will ultimately improve the quality of life for diabetic patients."

ELO Water is created through technology that allows a high level of oxygen to exist in the water in a unique, stable and bound form that is believed to allow quick absorption by the body, restoring its natural balance and enhancing health and overall well-being.

Positive results have been obtained from animal trials of ELO Water conducted overseas, Hyflux pointed out. Trials conducted by researchers at Monash University in Australia on transplanted human cancerous tumours in mice showed that ELO Water through oral application was able to be absorbed and penetrated into the tumours, enhancing oxygen levels inside the cancers and inhibiting their growth.